Should testosterone therapy be used in patients with hereditary hemochromatosis (HH)?

Testosterone Therapy in Hereditary Hemochromatosis

Testosterone replacement therapy should be used in patients with hereditary hemochromatosis who have documented hypogonadism, but only after achieving adequate iron depletion through phlebotomy, with careful monitoring for erythrocytosis.

Clinical Context and Pathophysiology

Hypogonadism is a recognized complication of hereditary hemochromatosis (HH), though its frequency has declined with earlier diagnosis and treatment 1. Iron overload can cause both primary testicular failure and secondary hypogonadotropic hypogonadism through pituitary iron deposition 1, 2. Importantly, testicular atrophy from HH does not reverse with iron removal 3, making this a permanent complication if iron depletion occurs too late.

Treatment Algorithm

Step 1: Prioritize Iron Depletion First

• Initiate therapeutic phlebotomy as the primary treatment for all HH patients with iron overload, targeting ferritin levels of 50-100 μg/L 3.
• Weekly or biweekly phlebotomy (500 mL blood removal) should be performed, checking hematocrit/hemoglobin before each session 3.
• Some hypogonadal men may experience restoration of normal testosterone levels and sexual function after iron depletion alone, without requiring testosterone therapy 2.

Step 2: Reassess Gonadal Function After Iron Depletion

• Reevaluate testosterone levels and gonadal function only after achieving target ferritin levels 2.
• In one study, 2 of 4 hypogonadal men (with both primary and secondary hypogonadism) had testosterone levels return to normal after phlebotomy, accompanied by restoration of sexual function 2.
• This critical step may eliminate the need for testosterone therapy in a subset of patients.

Step 3: Initiate Testosterone Only If Hypogonadism Persists

If hypogonadism persists after adequate iron depletion:

• Testosterone replacement is indicated for documented hypogonadism (testicular failure or hypogonadotropic hypogonadism) per FDA labeling 4.
• Long-term testosterone enanthate (250 mg intramuscularly every 4 weeks) has been successfully used in HH patients for up to 96 months 5.
• Benefits include improved general well-being, libido, potency, and increased bone mineral density (13.1% increase in lumbar spine over 24 months) 5, 6.

Critical Monitoring Requirements

Erythrocytosis Risk

The primary concern with testosterone in HH patients is erythrocytosis, which occurs more frequently with intramuscular injections than transdermal preparations:

• Intramuscular testosterone enanthate causes elevated hematocrit (>52%) in 43.8% of patients versus 15.4% with transdermal patches 7.
• Check hemoglobin and hematocrit levels periodically during long-term testosterone administration 4.
• This risk is particularly concerning in HH patients who already have a tendency toward elevated hematocrit from their underlying condition.
• Recent evidence shows that combined testosterone and SGLT-2 inhibitor therapy may increase erythrocytosis risk, particularly in patients with H63D heterozygosity 8.

Cardiovascular Considerations

• Erythrocytosis increases blood viscosity and may aggravate coronary, cerebrovascular, or peripheral vascular disease, especially in elderly patients 7.
• Testosterone has a neutral effect on lipid profiles at physiologic replacement doses 7.

Liver Function

• In a long-term study spanning 27.3 patient-years, testosterone treatment showed no deterioration of liver function in HH patients 5.
• Unlike alcoholic cirrhosis patients, HH patients treated with testosterone did not develop gynecomastia or portal vein thrombosis 5.

Practical Considerations

Younger HH patients with hypogonadism particularly benefit from testosterone therapy due to positive effects on bone health, sexual function, and quality of life 5, 6. However:

• Testosterone should not be used interchangeably between formulations (cypionate vs. propionate) due to different durations of action 4.
• Patients should report nausea, vomiting, skin color changes, ankle swelling, or persistent erections 4.
• Avoid vitamin C supplements during treatment, as they accelerate iron mobilization and may increase oxidant activity 3.

Common Pitfalls to Avoid

• Never initiate testosterone before achieving adequate iron depletion – this may worsen iron accumulation and increase cardiovascular risk through erythrocytosis.
• Do not assume all hypogonadal HH patients require lifelong testosterone – reassess after iron removal as some will recover spontaneously 2.
• Prefer transdermal over intramuscular formulations when possible to minimize erythrocytosis risk 7.
• Monitor for oligospermia with prolonged administration, and reduce dosage if excessive sexual stimulation or priapism develops 4.